Age-related macular degeneration (AMD) is a common cause of blindness in older individuals. To accelerate the understanding of AMD biology and help design new therapies, we executed a collaborative genome-wide association study, including >17,100 advanced AMD cases and >60,000 controls of European and Asian ancestry. We identified 19 loci associated at P < 5 × 10 −8 . These loci show enrichment for genes involved in the regulation of complement activity, lipid metabolism, extracellular matrix remodeling and angiogenesis. Our results include seven loci with associations reaching P < 5 × 10 −8 for the first time, near the genes COL8A1-FILIP1L, IER3-DDR1, SLC16A8, TGFBR1, RAD51B, ADAMTS9 and B3GALTL. A genetic risk score combining SNP genotypes from all loci showed similar ability to distinguish cases and controls in all samples examined. Our findings provide new directions for biological, genetic and therapeutic studies of AMD.
AMD is a highly heritable, progressive neurodegenerative disease that leads to loss of central vision through death of photoreceptors 1, 2 . In developed countries, AMD is the leading cause of blindness in those >65 years of age 3 . Genes in the complement pathway [4] [5] [6] [7] [8] [9] [10] [11] and a region of chromosome 10 (refs. 12,13) have now been implicated as the major genetic contributors to disease. Association has also been shown with several additional loci [14] [15] [16] [17] [18] [19] [20] , each providing an entry point into AMD biology and potential therapeutic targets.
To accelerate the pace of discovery in macular degeneration genetics, 18 research groups from across the world formed the AMD Gene Consortium in early 2010, with support from the National Eye Institute of the US National Institutes of Health ( Table 1, Supplementary  Table 1 and Supplementary Note). To extend the catalog of diseaseassociated common variants, we first organized a meta-analysis of genome-wide association studies (GWAS), combining data for >7,600 cases with advanced disease (with geographic atrophy, neovascularization or both) and >50,000 controls. Each study was first subjected to GWAS quality control filters (customized to take into account studyspecific features 21 as detailed in Supplementary Table 2 ) and analyzed at sites in the HapMap reference panel using statistical genotype imputation [22] [23] [24] [25] . Results were combined through meta-analysis 26 , and 32 variants representing loci with promising evidence of association were genotyped in an additional >9,500 cases and >8,200 controls ( Supplementary Tables 1-3 ; summary meta-analysis results are available online, see URLs). Our overall analysis of the most promising variants thus included >17,100 cases and >60,000 controls.
Our meta-analysis evaluated evidence for association at 2,442,884 SNPs ( Fig. 1) . Inspection of quantile-quantile plots ( Supplementary  Fig. 1 ) and the genomic control value (λ GC = 1.06) suggested that unmodeled population stratification did not significantly affect our findings (Supplementary Table 4 ). Joint analysis of discovery and follow-up studies 27 resulted in the identification of 19 loci with associations reaching P < 5 × 10 −8 ( Fig. 1 , Table 2 and Supplementary  Table 5 ). These 19 loci include all susceptibility loci previously reaching P < 5 × 10 −8 , except the 4q12 gene cluster, for which association was reported in a Japanese population. In addition, the set included seven loci reaching P < 5 × 10 −8 for the first time.
We evaluated heterogeneity between studies using the I 2 statistic, which compares the variability in effect size estimates between studies to that expected by chance 28 . We observed significant (P < 0.05/19) heterogeneity only for loci near ARMS2 (I 2 = 75.7%, P < 1 × 10 −6 ) and near CFH (I 2 = 85.4%, P < 1 × 10 −6 ). Although these two loci were significantly associated in every sample examined, the magnitude of association varied more than expected. To explore sources of heterogeneity, we carried out a series of subanalyses: we repeated the genome-wide meta-analysis, (i) adding an age adjustment, (ii) in neovascularization and geographic atrophy cases separately, (iii) in men and women separately, and (iv) in samples of European and Asian ancestry separately ( Fig. 2 and Supplementary Fig. 2 ). These subanalyses of the full GWAS data set did not identify additional loci with associations reaching P < 5 × 10 −8 ; furthermore, heterogeneity near CFH and ARMS2 remained significant in all subanalyses (I 2 > 65%, P < 0.001). Consistent with previous reports 17, 29, 30 , separate analysis of neovascularization and geographic atrophy cases showed ARMS2 risk alleles preferentially associated with risk of neovascularization disease (OR NV = 2.97, OR GA = 2.50, P difference = 0.0008), whereas CFH risk alleles preferentially associated with risk of geographic atrophy (OR NV = 2.34, OR GA = 2.80, P difference = 0.0006). We also observed large differences in effect sizes when stratifying by ancestry, with variants near CFH showing stronger evidence for association in Europeans (P = 1 × 10 −7 ) and those near TNFRSF10A showing stronger association among east Asians (P = 0.002). Potential explanations for these observations include differences in linkage disequilibrium (LD) between populations or differences in environmental or diagnostic factors that modify genetic effects.
l e t t e r s
Identifying the full spectrum of allelic variation that contributes to disease in each locus will require sequencing of AMD cases and controls. To conduct an initial evaluation of the evidence for multiple AMD risk alleles in the 19 loci described here, we repeated genomewide association analyses, conditioning on the risk alleles listed in Table 2 . We then examined each of the 19 implicated loci for variants with independent association (at P < 0.0002, corresponding to an estimate of ~250 independent variants per locus). This analysis resulted in the identification of the previously well-documented independently associated variants near CFH and C2-CFB 8, 10, 31, 32 and of additional independent signals near C3, CETP, LIPC, FRK-COL10A1, IER3-DDR1 and RAD51B (Supplementary Table 6 ). In four of these loci, the independently associated variants mapped very close to (within 60 kb of) the original signal. This shows that each locus can harbor multiple susceptibility alleles, encouraging searches for rare variants that elucidate disease-related gene function in these regions 33, 34 .
To prioritize our search for likely causal variants, we examined each locus in detail (see LocusZoom 35 plots in Supplementary Fig. 3 ) and investigated whether risk alleles for AMD were associated with changes in protein sequence, copy number variation or insertion-deletion (indel) polymorphisms. One quarter of associated variants altered protein sequence, either directly (N = 2) or through LD (r 2 > 0.6; N = 3) with a nearby nonsynonymous variant (Supplementary Table 7 ). Some coding variants implicate well-studied genes (ARMS2, C3 and APOE), whereas others helped prioritize nearby genes for further study. On chromosome 4q25, index SNP rs4698775 is in strong LD (r 2 = 0.88) with a potentially protein-damaging variant in CCDC109B 36 , encoding a coiled-coil domain-containing protein that might be involved in the regulation of gene expression. On chromosome 6q22, index SNP rs3812111 is a perfect proxy for a coding variant in COL10A1, encoding a collagen protein that could be important in maintaining the structure and function of the extracellular matrix. Notably, rs1061170 (encoding a p.His402Tyr alteration in CFH; NP_000177.2) was not in disequilibrium with rs10737680, the most strongly associated SNP in the CFH region but, instead, was tagged by a secondary, weaker association signal (Supplementary Tables 6 and 7) . This is consistent with previous haplotype analyses of the locus 10, 31, 32, 34, 37 .
We used publicly available data 38, 39 to determine whether any of our index SNPs might be proxies for copy number variants or indels, which are hard to directly interrogate with genotyping arrays. This analysis identified a single strong association (r 2 = 0.99) between rs10490924, a coding variant in the ARMS2 gene that is the peak of association at 10q26, and a 3′ UTR indel polymorphism associated with ARMS2 mRNA instability 40 .
Because index SNP rs10490924 is also in strong disequilibrium (r 2 = 0.90) with a nearby SNP, rs11200638, which regulates HTRA1 (ref. 41) , our data do not directly answer whether HTRA1 or ARMS2 is the causal gene in this locus. Although a common deletion of the CFHR1 and CFHR3 genes has been associated with AMD 42, 43 , there was only modest signal in this study, potentially due to LD with our most significantly associated variants in the locus (r 2 = 0.31 between rs10737680 and 1000 Genomes Project MERGED_DEL_2_6731) 34 .
Using RNA sequencing 44 , we examined the mRNA levels of 85 genes within 100 kb of our index SNPs in postmortem human retina (Supplementary Table 8 ). Of 19 independent risk-associated loci, 3 had no genes with expressed transcripts in retina tissue from either young or elderly individuals. Two genes showed differential expression in the postmortem retina of young (ages [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] and elderly (ages 75 and 77) individuals: CFH (P = 0.009) and VEGFA (P = 0.003), both with higher expression in the older individuals. Using previously published data 45 , we also examined the expression of associated genes in fetal and adult retinal pigment epithelium (RPE). This analysis showed higher C3 expression in adult RPE compared to fetal RPE (P = 0.0008). In addition to C3 and CFH, all the complement genes with detectable expression in the retina or RPE experiments showed higher expression levels in tissue from the older individuals.
To identify biological relationships among our genetic association signals, we catalogued the genes within 100 kb of the variants in each association peak (r 2 > 0.8 with the index SNP listed in Table 1 ). Ingenuity Pathway Analysis (IPA, Ingenuity Systems) highlighted several biological pathways, particularly the complement system and atherosclerotic signaling, that were enriched in the resulting set of 90 genes ( Table 3 and Supplementary Table 9 ). To account for features of GWAS (such as the different number of SNPs representing each gene), we carried out two additional analyses. First, we repeated our analysis for 50 sets of 19 control loci drawn from the National Human Genome Research Institute (NHGRI) GWAS catalog 46 . In these 50 control sets, Ingenuity enrichment P values for the complement system and for atherosclerosis signaling genes were exceeded 16% and 32% of the time, respectively (although these 2 specific pathways were never implicated in a control data set). Second, we repeated our Figure 1 Summary of GWAS results. Summary of genome-wide association results in the discovery GWAS sample. Previously described loci with associations reaching P < 5 × 10 −8 are labeled in blue; new loci with associations reaching P < 5 × 10 −8 for the first time after follow-up analysis are labeled in green. The dashed horizontal lines represent thresholds for follow-up (P < 1 × 10 −5 , orange) and genome-wide significance (P < 5 × 10 −6 , red) as well as a discontinuity in the y axis (at P < 1 × 10 −16 , gray).
npg l e t t e r s enrichment analyses using the Interval-based Enrichment Analysis Tool for Genome-Wide Association Studies (INRICH) 47 , which is specifically designed for the analysis of GWAS but accesses a more limited set of annotations. The INRICH analyses showed enrichment for genes encoding collagen and extracellular region proteins (both with P = 1 × 10 −5 ; P adjusted = 0.0006 after adjustment for multiple testing), complement and coagulation cascades (P = 0.0002; P adjusted = 0.03), lipoprotein metabolism (P = 0.0003; P adjusted = 0.04) and regulation of apoptosis (P = 0.0009; P adjusted = 0.09) (Supplementary Table 10 ).
To explore the connections between our genetic association signals, we tested for interaction between pairs of risk alleles, looking for situations where joint risk was different than the expectation based on marginal effects. This analysis comprised 171 pairwise tests of interaction, of which 9 were nominally significant (P < 0.05; Supplementary Table 11) , consistent with expectations by chance. The strongest observed interaction involved risk alleles at rs10737680 (near CFH) and rs429608 (near C2-CFB), the only association that remained significant after adjusting for multiple testing (P = 0.000052 < 0.05/171 = 0.00029). Figure 3 Risk score analysis. We calculated a risk score for each individual, defined as the product of the number of risk alleles at each locus and the associated effect size for each allele (measured on the log-odds scale). The plot summarizes the ability of these overall genetic risk scores to distinguish cases and controls. Analyses were carried out using the 19 SNPs that reached P < 5 × 10 −8 here, the 12 SNPs previously reaching this threshold and the 7 new variants. All results reported here include a genomic control correction for individual studies and also for the final meta-analysis 51 . A summary of all gene name abbreviations used in this table and elsewhere in the manuscript is provided in supplementary table 5. EAF is the allele frequency of the risk-increasing allele. Chr., chromosome.
npg l e t t e r s Individuals carrying risk alleles at both these loci were at slightly higher risk of disease than expected. The proportion of variability in the risk of AMD that is due to genes, or heritability, has been estimated at 45-70% (ref. 2) . Estimating the proportion of disease risk explained by the susceptibility loci identified 48 depends greatly on the disease prevalence, which is difficult to estimate in our sample, as it includes cases and controls of different ages collected through a variety of ascertainment schemes. Using a model that assumes an underlying normally distributed but unobserved disease risk score or liability 49 , the 19 loci described here accounted for between 10% (if AMD prevalence was close to 1%) and 30% (if AMD prevalence was closer to 10%) of the variability in disease risk (corresponding to 15-65% of the total genetic contribution to AMD). The variants representing the association peaks at loci previously reaching genome-wide significance accounted for the bulk of this variability: the new loci identified here accounted for 0.5-1.0% of the total heritability of AMD, whereas secondary signals at new and known loci accounted for 1.5-3.0% of the total heritability.
We report here the most comprehensive genetic association study of macular degeneration yet conducted, involving 18 international research groups and a large set of cases and controls. Our data identify 19 susceptibility loci, including 7 loci with associations reaching P < 5 × 10 −8 for the first time, nearly doubling the number of known AMD-associated loci outside the complement pathway. Our results show that some susceptibility alleles show different associations across ancestry groups and might be preferentially associated with specific subtypes of disease. As with other GWAS meta-analysis, differences in genotyping methods, quality control steps and imputation strategies between samples might have a minor effect in our results-future studies with more uniform approaches across larger sample sizes might uncover more association signals. A conundrum of macular degeneration genetics remains that the loci identified so far contribute to both geographic atrophy and neovascular disease, two different phenotypes of advanced disease. In our sample, subtype-specific GWAS analyses considering geographic atrophy or neovascular cases only did not identify additional risk loci. Consistent with observations for other complex diseases 39 , the majority of common disease susceptibility alleles do not alter protein sequences and are not associated with indels of coding sequences or with copy number variation. We expect that the loci identified here will provide an ideal starting point for studying the contribution of rare variation in AMD 33, 34 .
In contrast to most other complex diseases, a risk score combining information across our 19 loci can distinguish cases and controls relatively well (area under the receiver operator curve (AUC) = 0.52, including only new loci, or AUC = 0.74, including new and previously reported loci; Fig. 3 and Supplementary Fig. 4) . It might be possible to use similar scores to identify and prioritize at-risk individuals so they receive preventative treatment before the onset of disease 50 . Monotherapies are increasingly used to manage neovascularization disease but offer only a limited repertoire of treatment options to patients. The identification of novel genes and pathways involved in disease enables the pursuit of a larger range of disease-specific targets for the development of new therapeutic interventions. We expect that future therapies directed at earlier stages of the disease process will allow patients to retain visual function for longer periods, improving the quality of life for individuals with AMD. 
METhODS
Methods and any associated references are available in the online version of the paper.
Note: Supplementary information is available in the online version of the paper.
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ONLINE METhODS
Genome-wide scan for advanced AMD association including follow-up analysis. All participating studies were reviewed and approved by local institutional review boards. In addition, subjects gave informed consent before enrollment.
Study-specific association analysis for discovery. Genotyping was performed on a variety of different platforms summarized in Supplementary Table 2 .
Each study group submitted results from association tests using genotyped and imputed data with the allelic dosages computed with either MACH 25 , IMPUTE 23 , BEAGLE 24 or snpStats 52 using the HapMap 2 reference panels. The CEU panel (Utah residents of Northern and Western European ancestry) was used as a reference for imputation-based analyses for most samples (predominantly of European ancestry), with two exceptions: for the JAREDS samples (predominantly of east Asian ancestry), the Han Chinese in Beijing, China (CHB) and Japanese in Tokyo, Japan (JPT) panel was used as a reference, and, for the VRF samples (predominantly of south Asian ancestry), the combined CEU, CHB and JPT panels were used 22, 53 . For most data sets, association tests were run under a logistic regression model using either PLINK 54 , Mach2dat 25 , ProbABEL 55 or snpStats 52 , although, for one data set containing related individuals, the generalized estimating equations algorithm 56 was implemented in R 57 . In addition to the primary analysis that tested for SNP associations with advanced AMD unadjusted for age, an age-adjusted sensitivity analysis was conducted by each group with available age information. Each group also provided stratified results by sex or AMD subtype (geographic atrophy or neovascularization disease), as long as the sample size per stratum exceeded 50 subjects. For all analyses, study-specific control for population stratification was conducted (Supplementary Table 4) .
Study-specific association analysis for follow-up.
Genotyping of the selected SNPs was performed on different platforms. The same models and sensitivity and stratified analyses were computed by each follow-up partner, and SNPs with insufficient call rate were excluded on the basis of study-specific thresholds. If the index SNP could not be genotyped, a highly correlated proxy was used whenever possible (Supplementary Tables 2 and 3) .
Quality control before meta-analysis. Before meta-analysis, all study-specific files underwent quality control procedures to check for completeness and plausible descriptive statistics on all variables as well as for compliance of allele frequencies with HapMap 58 . In addition, we excluded individual study SNP results from meta-analysis (i) for discovery if imputation quality measures were too low (MACH and PLINK < 0.3; SNPTEST < 0.4) or if effect size (|β|) or standard error was too extreme (≥ 5), indicating instability of the estimates, or (ii) for follow-up if Hardy-Weinberg equilibrium was violated (P < 0.05/32).
Meta-analyses.
For both discovery and follow-up, we performed meta-analyses using the inverse variance-weighted fixed-effect model, which pools the effect sizes and standard errors from each participating GWAS. Using an alternative-weighted z-score method, which is based on a weighted sum of z-score statistics, we obtained a very similar set of test statistics (correlation of -log 10 (P value) > 0.98). All analyses were performed using METAL 26 and R. For the discovery stage, we applied two rounds each of genomic control corrections to the individual GWAS results and the combined meta-analysis results 51 . All results were analyzed and validated among four independent teams.
Extended analyses for the identified AMD-associated loci. Extended analyses were conducted on the identified loci and particularly on the top SNP at each locus.
Second signal analysis. To detect potential independent signals within the identified AMD-associated loci, each study partner with genotypes for all identified SNPs available reanalyzed their data for all SNPs in the respective loci (index SNP ± 1 Mb) using a logistic regression model containing all identified index SNPs. Quality control procedures were performed as before. Meta-analysis was performed on the β estimate for each SNP, applying the effective sample size-weighted z-score method and two rounds of genomic control correction. The significance threshold (P < 0.05) for an independent association signal within any of the identified loci was Bonferroni adjusted using the average effective number of SNPs involved across the identified loci as determined by SNPSpD 59 . Thirteen studies contributed to this analysis, including 7,489 cases and 51,562 controls.
Interaction analysis. Using prespecified R scripts (see URLs), GWAS partners performed 171 logistic regression analyses modeling the pairwise interactions of the 19 index SNPs, assuming an additive model for main and interaction effects. Study-specific covariates were included in the models, if required. For each study, quality control included a check for consistency of the main SNP effects between discovery and interaction analyses. SNPs with low imputation quality measure and pairs with |β| > 5 or standard error > 5 were excluded before meta-analysis was performed on the interaction effects with the inverse variance-weighted fixed-effect model in METAL. Twelve studies contributed to this analysis, including 6,645 cases and 49,410 controls.
Genetic risk score. Effect sizes, β j , for each of the 19 SNPs were calculated in the meta-analysis described above and normalized by
where j = 1,…,19. Using these values as weights, each study partner with data available for all 19 SNPs computed the genetic risk score for an individual as a normalized weighted sum of the AMD risk-increasing alleles among the identified SNPs, with
here x ij is the genotype of the ith individual at the jth SNP, such that S i ranges from 0 to 2. Data for these calculations were available from 12 studies, including 7,195 cases and 49,149 controls.
For each study, we used leave-one-out cross-validation to access the prediction of the risk score. For the kth subject, we fitted a logistic regression model from all subjects in the study excluding the kth subject as
where α is the intercept and γ is the effect of the genetic risk score. The fitted probability of the kth subject was then estimated. e sorted the fitted probabilities and calculated sensitivity and specificity by varying the risk threshold (the value compared with the fitted probability to dichotomize the subjects into cases or controls) from 0 to 1. These estimates of sensitivity and specificity were used to compute the AUC of the receiver operating curve.
Identification of correlated coding variants and tagged non-SNP variation.
LD estimates were calculated using genotype data from the identified risk loci (index SNPs ± 500 kb) in individuals with European ancestry from the 1000 Genomes Project (March 2012 release) 60 or from HapMap (release 28) 58 . Variants correlated (r 2 > 0.6) with one of the GWAS index SNPs were identified using PLINK 54 . To identify coding variants, all correlated variants were mapped against RefSeq transcripts using ANNOVAR 61 .
Gene expression. We evaluated the expression in retina of genes within 100 kb of 1 of the 19 index SNPs, as well as of several retina-specific, RPE-specific and housekeeping genes unrelated to AMD for comparison (RNA sequencing data from 3 young (17-35 years) and 2 elderly (75 and 77 years) individuals). We also analyzed expression in fetal and adult RPE (data in the Gene Expression Omnibus database 45 ; GSE18811). Expression was analyzed using previously described protocols 44 (Supplementary Table 8) .
npg Pathway analyses. Functional enrichment analysis was performed using IPA software. Any gene located within 100 kb of a SNP in high LD (r 2 > 0.8) with one of the index SNPs was considered a potential AMD risk-associated gene and was included in subsequent pathway enrichment analysis. LD estimates were calculated as described above. Applying these inclusion filters, 90 genes were implicated by our 19 replicated AMD-associated SNPs (Supplementary Table 8 ). Because genes with related function sometimes cluster in the same locus, we trimmed gene lists during analysis so that only one gene per locus was used to evaluate enrichment for each pathway. The P value of the association between our gene list and any of the canonical pathways and/or functional gene sets as annotated by IPA's Knowledge Base was computed using a one-sided Fisher's exact test. The Benjamini-Hochberg method was used to estimate FDR. To evaluate the significance of observed enrichment, we repeated our Ingenuity analysis starting with 50 lists of 19 SNPs randomly drawn from the NHGRI GWAS catalog 46 and, again, using the INRICH tool 62 . When using INRICH, we used gene sets defined in the Molecular Signatures Database (MSigDB) 47 (ver3.0) representing manually curated canonical pathway, gene ontology (GO) biological process and cellular component and molecular function gene sets (C2:CP, C5:BP, C5:CC and C5:MF). We provided INRICH with our full GWAS SNP list and allowed it to carry out 100,000 permutations, matching selected loci in terms of gene count, SNP density and total number of SNPs.
